ECSP055700A - Uso de derivados de 4-piridil-metil-ftalazina para la fabricación de un medicamento para el tratamiento de síndromes mielodisplásticos - Google Patents

Uso de derivados de 4-piridil-metil-ftalazina para la fabricación de un medicamento para el tratamiento de síndromes mielodisplásticos

Info

Publication number
ECSP055700A
ECSP055700A EC2005005700A ECSP055700A ECSP055700A EC SP055700 A ECSP055700 A EC SP055700A EC 2005005700 A EC2005005700 A EC 2005005700A EC SP055700 A ECSP055700 A EC SP055700A EC SP055700 A ECSP055700 A EC SP055700A
Authority
EC
Ecuador
Prior art keywords
ftalazine
piridil
derivatives
methyl
manufacture
Prior art date
Application number
EC2005005700A
Other languages
English (en)
Inventor
Margaret Han Dugan
Alan List
Original Assignee
Novartis Ag
Arizona Board Of Regents A Nom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Arizona Board Of Regents A Nom filed Critical Novartis Ag
Publication of ECSP055700A publication Critical patent/ECSP055700A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para el tratamiento de síndromes mielodisplásticos, el cual comprende administrar una cantidad terapéuticamente efectiva de un derivado de 4-piridil-metil-ftalazina, a un animal de sangre caliente que lo necesite.
EC2005005700A 2002-09-24 2005-03-23 Uso de derivados de 4-piridil-metil-ftalazina para la fabricación de un medicamento para el tratamiento de síndromes mielodisplásticos ECSP055700A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24

Publications (1)

Publication Number Publication Date
ECSP055700A true ECSP055700A (es) 2005-08-11

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005700A ECSP055700A (es) 2002-09-24 2005-03-23 Uso de derivados de 4-piridil-metil-ftalazina para la fabricación de un medicamento para el tratamiento de síndromes mielodisplásticos

Country Status (22)

Country Link
US (1) US20060128716A1 (es)
EP (1) EP1545534B1 (es)
JP (1) JP2006502195A (es)
KR (1) KR20050074450A (es)
CN (1) CN100372535C (es)
AT (1) ATE359789T1 (es)
AU (1) AU2003299065B2 (es)
BR (1) BR0314647A (es)
CA (1) CA2499738A1 (es)
CR (1) CR7754A (es)
DE (1) DE60313344T2 (es)
EC (1) ECSP055700A (es)
ES (1) ES2285251T3 (es)
HR (1) HRP20050281A2 (es)
MX (1) MXPA05003161A (es)
NO (1) NO20051936L (es)
PL (1) PL374696A1 (es)
PT (1) PT1545534E (es)
RS (1) RS20050228A (es)
RU (1) RU2353364C2 (es)
WO (1) WO2004028542A1 (es)
ZA (1) ZA200502212B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839682D1 (de) * 1997-10-15 2008-08-14 Polarx Biopharmaceuticals Inc Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von nicht-Hodgkihn-Lymphome
JP2009507849A (ja) 2005-09-09 2009-02-26 ブリストル−マイヤーズ スクイブ カンパニー 非環状ＩＫｕｒインヒビター

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP1165085B1 (en) * 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
JP2003515558A (ja) * 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療するためのメチロール含有化合物の使用

Also Published As

Publication number Publication date
WO2004028542A1 (en) 2004-04-08
RU2353364C2 (ru) 2009-04-27
BR0314647A (pt) 2005-08-02
EP1545534B1 (en) 2007-04-18
DE60313344T2 (de) 2008-01-03
AU2003299065A1 (en) 2004-04-19
JP2006502195A (ja) 2006-01-19
KR20050074450A (ko) 2005-07-18
DE60313344D1 (de) 2007-05-31
EP1545534A1 (en) 2005-06-29
HRP20050281A2 (en) 2006-07-31
CN1684684A (zh) 2005-10-19
PT1545534E (pt) 2007-06-22
CA2499738A1 (en) 2004-04-08
CR7754A (es) 2005-12-02
AU2003299065B2 (en) 2006-10-26
US20060128716A1 (en) 2006-06-15
CN100372535C (zh) 2008-03-05
ES2285251T3 (es) 2007-11-16
ATE359789T1 (de) 2007-05-15
MXPA05003161A (es) 2005-09-12
RU2005112711A (ru) 2006-02-27
RS20050228A (en) 2007-08-03
NO20051936L (no) 2005-06-23
ZA200502212B (en) 2006-02-22
PL374696A1 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
CY1115484T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
DE602004024900D1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
ATE541582T1 (de) Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
ECSP055844A (es) Nuevos compuestos triciclicos
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
DE602004012418D1 (de) Piperazinderivate und anwendungsverfahren
ATE413187T1 (de) Pharmazeutische zusammensetzungen mit interferon- tau
SE0004101D0 (sv) New use
ECSP055700A (es) Uso de derivados de 4-piridil-metil-ftalazina para la fabricación de un medicamento para el tratamiento de síndromes mielodisplásticos
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose
SE0004827D0 (sv) Therapeutic compounds
BR0316010A (pt) Combinação
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου
BR0112123A (pt) Composto
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
MX2007002532A (es) Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol.
ATE334675T1 (de) Arzneimittel enthaltend substituierte 2,5- diaminomethyl-1h-pyrrole
CY1114949T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
DOP2003000766A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes
SE0103539D0 (sv) New Use